Synthetic Vulnerabilities in the KRAS Pathway

SIMPLE SUMMARY: Despite recent dramatic progress, developing drugs that target oncogenic KRAS or its key effectors remains a major challenge for cancer research. Improving our understanding of the underlying biology of KRAS in cancer will identify potential codependent vulnerabilities or synthetic l...

Descripción completa

Detalles Bibliográficos
Autores principales: Roman, Marta, Hwang, Elizabeth, Sweet-Cordero, E. Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221492/
https://www.ncbi.nlm.nih.gov/pubmed/35740503
http://dx.doi.org/10.3390/cancers14122837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221492/
https://www.ncbi.nlm.nih.gov/pubmed/35740503
http://dx.doi.org/10.3390/cancers14122837

Ejemplares similares